Quibim
Quibim turns MRI, CT and PET scans into regulatory-cleared quantitative imaging biomarkers for prostate, brain, liver, breast and lung.
If your question is 'what is the number for this lesion, and will a regulator accept it,' Quibim is a short list candidate. The organ-by-organ licensing is the real cost story, so model a rollout tissue by tissue rather than a single platform purchase. Pass if you need acute triage — stroke, fracture — where this isn't the workflow.
Verified 21h ago · liveness 65/100 · cite: rightaichoice.com/tools/quibim
- Radiologists who need regulatory-cleared quantitative biomarkers for prostate, brain, liver, breast or lung imaging
- Biopharma imaging teams stratifying trial candidates and monitoring toxicity or response with radiomics features
- Clinical researchers correlating large imaging archives with EHR and multi-omics datasets
- Hospitals in the US, Canada, Europe or the UK needing cleared, HIPAA/GDPR-compliant imaging AI
- Small clinics without enterprise IT support or a dedicated imaging-software budget
- Emergency radiology triage such as stroke or fracture detection
- Buyers who expect one purchase to switch on every organ — products are licensed separately
We scan live Reddit threads, YouTube comments, X posts, G2 reviews and other communities — and hand you an honest verdict in under a minute.
- Honest verdict, not marketing
- Real pros & cons from real users
- Attributed quotes with receipts
3 free scans · no card needed
Skip Quibim if you need emergency radiology triage such as stroke or fracture detection, or if you want one license covering every organ — its products are licensed tissue-by-tissue as regulated medical devices.
Each QP- product (Prostate, Brain, Liver, Breast, Lung) is licensed separately, so full organ coverage means multiple product contracts rather than one platform fee.
Quibim sells to enterprise healthcare systems and biopharma R&D teams as a set of regulatory-cleared medical device products, so the cost profile sits well above consumer or single-clinic imaging AI tools that ship without FDA, CE, or Health Canada clearance. Buyers in this category are typically comparing Quibim against other cleared quantitative imaging vendors plus in-house radiology software budgets, not against cheap point tools.
In short
Quibim — Quibim turns MRI, CT and PET scans into regulatory-cleared quantitative imaging biomarkers for prostate, brain, liver, breast and lung. Best for Radiologists who need regulatory-cleared quantitative biomarkers for prostate, brain, liver, breast or lung imaging, Biopharma imaging teams stratifying trial candidates and monitoring toxicity or response with radiomics features, Clinical researchers correlating large imaging archives with EHR and multi-omics datasets. Contact Sales pricing.
No head-to-head comparison for Quibim yet — the alternatives below are the closest matches we list.
What's new in Quibim
Checked todayAcross the latest 6 updates: 6 news mentions.
Radiomic feature reproducibility in neuroblastoma T2-weighted MRI
Quibim Info Hub publishes a reproducibility analysis of radiomic features from T2-weighted MRI after processing and segmentation alterations in neuroblastoma tumors.
Imaging features model predicts CAR-T outcomes in B-cell lymphoma
Quibim Info Hub features research using an imaging features-based model to predict survival, neurotoxicity and response in B-cell lymphoma patients treated with CAR-T therapy.
Quality control method for 3D T1-weighted MR hippocampus volumetry
Quibim Info Hub covers an easy-to-use quality control approach for 3D gradient echo T1-weighted MR sequences to improve test-retest stability of hippocampus volumetry.
Pre-trained foundation model for MRI classification of rectal cancer invasion
Quibim Info Hub highlights a pre-trained foundation model framework for multiplanar MRI classification of extramural vascular and mesorectal fascia invasion in rectal cancer.
Graphtrack: automated longitudinal lesion tracking in CT via graph learning
Quibim Info Hub features Graphtrack, a method for automated longitudinal lesion tracking in CT using local-global reasoning with contrastive and graph learning.
Quibim Info Hub highlights research on healthcare innovation sustainability
Quibim's Info Hub published an item on technological innovation in healthcare, covering challenges, opportunities and sustainability impact.
What people actually say about Quibim — is it worth it?
We ran a structured research pass across product reviews, community discussions, and post-purchase forum threads to surface the patterns vendors won't publish themselves. Below: the recurring strengths, the hidden costs people mention most, and the cohort that consistently regrets adopting this tool.
9 mentions across 1 source (YouTube) · researched Aug 21, 2026.
Average across the 1 source that answered — each source counts once, not each post.
- +Regulatory clearances (FDA, CE, Health Canada) give clinical credibility.
- +Tissue-agnostic platform for diverse imaging biomarker extraction.
- +Integrates with PACS for smooth clinical workflow.
- +HIPAA, GDPR, ISO 27001 compliance ensures data security.
- +Linking imaging with EHR and multi-omics supports biomarker discovery.
- −Nearly zero independent community feedback online.
- −Lack of public user success stories or case studies.
- −Pricing opaque, likely enterprise-level costs.
- −No evidence of simple self-service deployment; requires enterprise IT.
- −Advanced skill level may deter smaller practices.
- • No public pricing; may require annual contracts and Azure usage fees.
- • Possibly per-scan or per-module fees for each QP product.
Viability Score
How well maintained and how widely used is Quibim? Built from what the vendor actually publishes (docs, changelog, tutorials, integrations, pricing), whether the site is live, and how much real users discuss it. How we calculate this
Last calculated: October 2026
How we score →Key Features
- Tissue-agnostic extraction of radiomics and deep-learning imaging features from MRI, CT and PET
- QP-Prostate®: PI-RADS-compliant prostate MRI analysis with FDA, CE and Health Canada clearance
- QP-Brain®: brain volumetry and white matter hyperintensity (WMH) analysis
- QP-Liver®: quantifies fat and iron concentration for steatosis and iron overload
- QP-Breast®: CE and UKCA-marked AI for breast cancer detection via MRI, launched 2 July 2026
- QP-Lung®: lung imaging analysis
- QP-Insights®: web-based cloud platform to manage, store and analyze large-scale multi-omics and imaging data
- Harmonizes image signal, contrast and noise variability across scanner manufacturers
- Links imaging data with EHR records and multi-omics datasets
- Automated whole-abdomen and liver segmentation to cut manual segmentation time
- PACS integration for clinical workflow
- Radiomics plus PI-RADS plus clinical variable modeling for significant prostate cancer prediction and biopsy guidance
- Cloud deployment on Microsoft Azure with encryption during storage, transfer and at file level
- ISO 27001:2022 certified with HIPAA and GDPR-compliant data processing and storage
- Web-based cloud access for research and clinical studies
About Quibim
Quibim is a cloud-based, tissue-agnostic medical imaging platform that pulls radiomics and deep-learning features out of MRI, CT and PET scans and converts them into standardized quantitative biomarkers. The buyer is a hospital radiologist, a biopharma imaging team, or a clinical researcher who needs a reproducible number per scan instead of another qualitative read. The clinical catalog is sold organ by organ as software-as-a-medical-device. QP-Prostate® handles PI-RADS-compliant prostate MRI reads and holds FDA and CE clearance plus a Health Canada licence granted in June 2026. QP-Brain® covers brain volumetry and white matter hyperintensity analysis. QP-Liver® quantifies fat and iron concentration for steatosis and iron overload and automates whole-abdomen and liver segmentation. QP-Breast® launched 2 July 2026 as a CE and UKCA-marked tool for breast cancer detection via MRI. QP-Lung® covers lung imaging. QP-Insights® is the layer underneath: it indexes, stores and harmonizes imaging data into a standardized image quality that narrows signal, contrast and noise variability across scanner manufacturers, then links that data to EHR records and multi-omics sources. Clinical products plug into PACS, everything runs on Microsoft Azure with encryption during storage, transfer and at file level, and Quibim holds ISO 27001:2022 certification with stated HIPAA and GDPR compliance. A Quibim-published study reported in August 2026 found that combining radiomics, PI-RADS scoring and clinical variables improves significant prostate cancer prediction and biopsy guidance. Against general-purpose imaging AI that spans organs, Quibim goes deep per tissue and bets on cleared, quantitative output for enterprise healthcare and life-sciences buyers.
Behind the Verdict
Quibim's pitch is defensible because it is narrow in the right place. Plenty of imaging AI ships a detection overlay that a radiologist then has to trust on faith; Quibim ships cleared measurement products where the output is a value, a segmentation volume, or a quantified concentration. For a prostate MRI program that already runs PI-RADS, QP-Prostate® is the logical first buy, and the August 2026 study on combining radiomics with PI-RADS and clinical variables gives you a credible internal argument for why the extra quantification earns its place in the read. Where I'd reach for it: when reproducibility across scanners is the blocker. The QP-Insights® harmonization layer is the underrated piece — minimizing signal, contrast and noise variability between manufacturers matters more than any single organ module if you are running multi-site research or a trial that spans hospitals. Where it bites: licensing. Each organ product is separate, so a department that wants prostate, brain and liver is negotiating three times and training staff on three interfaces. Budget for a phased rollout, not a site license that turns everything on. Second caveat: it is a post-processing and quantification stack, not a triage tool. Emergency use cases like stroke or fracture detection sit outside what these products do, so don't let a procurement committee fold it into an acute-care conversation. The closest comparison is the general-purpose imaging AI vendors that market broad organ coverage from one contract. They win on breadth of paperwork; Quibim wins on depth of validated output per tissue. If your clinical question is 'is this lesion suspicious,' either category can help. If the question is 'how much fat, how much iron, how many milliliters, and does that number hold across two
Researching Quibim? Get your full AI stack in 60 seconds.
Free, no signup — tell us your goal and get tools matched to your budget & existing stack.
Real-world workflow fit
Concrete scenarios for the personas Quibim actually fits — and what changes day-one when you adopt it.
A prostate MRI is ordered; the scan flows from PACS into QP-Prostate®, which produces PI-RADS-compliant quantitative measurements and standardized input data for interpretation.
Outcome: The radiologist reads from objective quantitative output rather than a purely qualitative impression, and reads are standardized across scanners and readers.
Trial enrollment needs imaging-based stratification; the team uses QP-Insights® to index and harmonize enrolled patients' imaging data and link it to EHR and multi-omics signals.
Outcome: Candidates more likely to respond are identified before randomization, and drug-response and toxicity signals are monitored over the course of the trial.
A research project needs radiomics features joined to processed EHR data across a large multi-scanner cohort; QP-Insights® harmonizes scanner variability in signal, contrast, and noise, then links the imaging to EHR and multi-omics sources.
Outcome: Radiomics features can be extracted and correlated at scale without scanner-to-scanner noise confounding the analysis.
Use Cases
- Identify clinical trial candidates based on imaging biomarkers from routine scans
- Quantify tumor heterogeneity and predict treatment response in lung cancer
- Standardize prostate MRI reads with PI-RADS-compliant AI analysis
- Monitor liver steatosis and iron overload non-invasively over time
- Accelerate brain volumetry for neurodegenerative disease diagnosis and progression tracking
- Stratify neuroblastoma patients using AI algorithms from PET/CT images
- Predict survival and neurotoxicity in B-Cell lymphoma patients treated with CAR-T therapy
- Detect breast cancer via MRI with a CE and UKCA-marked AI tool in Europe and the UK
Models Under the Hood
as of 2026-10-16
Limitations
- Quibim is a regulatory-cleared clinical and research product line rather than a general-purpose chatbot: its five QP products (Prostate, Brain, Liver, Breast, Lung) are licensed separately alongside the QP-Insights® data platform.
- It is built for enterprise healthcare and life-sciences buyers (hospitals, biopharma) rather than small clinics or individual practitioners.
- Because it operates as a SaaS platform on Microsoft Azure, adoption requires integration work with existing hospital systems such as PACS and EHR.
as of 2026-09-29
Verification history
We have re-verified Quibim 19 times since . Each pass re-reads the vendor's own pages and re-checks every listed field against that evidence; passes where nothing had changed are marked as such.
- — re-verified summary, description, our verdict, our analysis, pricing model, pricing tiers, features, integrations, who it suits, who should skip it
- — re-verified summary, description, our verdict, our analysis, pricing model, pricing tiers, features, integrations, who it suits, who should skip it
- — re-verified summary, description, our verdict, our analysis, pricing model, pricing tiers, features, integrations, who it suits, who should skip it
- — re-verified summary, description, our verdict, our analysis, pricing model, pricing tiers, features, integrations, who it suits, who should skip it
- — re-verified summary, description, our verdict, our analysis, pricing model, pricing tiers, features, integrations, who it suits, who should skip it
- — re-verified summary, description, our verdict, our analysis, pricing model, pricing tiers, features, integrations, who it suits, who should skip it
Showing the 6 most recent of 19 verification passes.
Free to cite with attribution — this page re-verifies continuously.
Where the pricing makes sense
The company stage and team size where Quibim's pricing actually pencils out — and where peers do it cheaper.
Quibim sells to enterprise healthcare systems and biopharma R&D teams as a set of regulatory-cleared medical device products, so the cost profile sits well above consumer or single-clinic imaging AI tools that ship without FDA, CE, or Health Canada clearance. Buyers in this category are typically comparing Quibim against other cleared quantitative imaging vendors plus in-house radiology software budgets, not against cheap point tools.
Setup time & first value
How long it actually takes to get something useful out of Quibim — broken out by persona, not the marketing-page minute.
Expect a multi-week onboarding rather than a same-day setup. Hospitals must connect QP-Products to their PACS and work through IT, security review, and role-based access provisioning — a June 2026 engineering change cut RBAC verification time by 90%, which shortens that step. Biopharma and research teams using QP-Insights® have additional work to index and harmonize existing imaging data and link
Switching to or from Quibim
How to bring data in from common predecessors and how to get it back out — written for the switcher, not the buyer.
- →From manual radiologist reads: route prostate MRI through QP-Prostate® to get PI-RADS-compliant quantitative output in place of qualitative impressions.
- →From a single-organ imaging AI tool: add QP-products tissue-by-tissue and consolidate imaging data management under QP-Insights®.
- →From a research image archive: load the archive into QP-Insights® to harmonize scanner variability and link imaging to EHR and multi-omics sources.
- →From PACS-only workflow: connect QP-Products to PACS so cleared analysis runs alongside the existing reading workflow.
- ↗To a general-purpose imaging AI vendor: you lose the tissue-specific regulatory clearances and the QP-Insights® harmonization layer.
- ↗To an in-house radiomics pipeline: you take on the harmonization, EHR linking, and regulatory maintenance work Quibim handles.
- ↗To a single-organ point tool: you keep only that organ's capability and drop the multi-product clearing across prostate, brain, liver, breast, and lung.
Integrations
Resources & Guides
- Resourcequibim.com
Info Hub - AI Imaging, Radiomics & Clinical Insights
Blog, white papers, scientific publications, webinars and KOL conversations on AI applied to medical imaging. Curated by Quibim — pioneers in radiomics.
- Resourcequibim.com
Info Hub - AI Imaging, Radiomics & Clinical Insights
Blog, white papers, scientific publications, webinars and KOL conversations on AI applied to medical imaging. Curated by Quibim — pioneers in radiomics.
- Resourcequibim.com
Info Hub - AI Imaging, Radiomics & Clinical Insights
Blog, white papers, scientific publications, webinars and KOL conversations on AI applied to medical imaging. Curated by Quibim — pioneers in radiomics.
- Resourcequibim.com
Info Hub - AI Imaging, Radiomics & Clinical Insights
Blog, white papers, scientific publications, webinars and KOL conversations on AI applied to medical imaging. Curated by Quibim — pioneers in radiomics.
- Resourcequibim.com
Info Hub - AI Imaging, Radiomics & Clinical Insights
Blog, white papers, scientific publications, webinars and KOL conversations on AI applied to medical imaging. Curated by Quibim — pioneers in radiomics.
- Resourcequibim.com
Info Hub - AI Imaging, Radiomics & Clinical Insights
Blog, white papers, scientific publications, webinars and KOL conversations on AI applied to medical imaging. Curated by Quibim — pioneers in radiomics.
Tutorials & Learning
YouTube returned 6 videos for “Quibim”, and we withheld 6: 6 could not be judged, because “Quibim” is a single word that other videos use for other things. We are showing none, because we could not prove any of them are about Quibim.
Official links
Tools that pair well with Quibim
Common stack mates teams adopt alongside Quibim, with the specific reason each pairing earns its keep.
Paige AI
FDA-cleared AI for cancer pathology: prostate, breast, GI and pan-cancer detection on H&E slides, plus Virchow foundation models for research.
Verge Genomics
All-in-human AI foundation models for precision neurology — vBx-1.0 predicts brain activity and therapy response from a blood draw.
PathAI
PathAI's AISight Dx brings FDA-cleared digital pathology and AI biomarker algorithms to labs and biopharma trials.
Alternatives to Quibim
View allPaige AI
FDA-cleared AI for cancer pathology: prostate, breast, GI and pan-cancer detection on H&E slides, plus Virchow foundation models for research.
Verge Genomics
All-in-human AI foundation models for precision neurology — vBx-1.0 predicts brain activity and therapy response from a blood draw.
Frequently Asked Questions
Used Quibim? Help shape our editorial sentiment research.